These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29950152)

  • 21. [Changes of regulatory T cell number in hepatocellular carcinoma-bearing mice and its relationship with tumor growth].
    Zhang P; Zhang LN; Zhu FL; Wang Q; Wang XY; Li HY; Liu CM; Gao F; Liu CH
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):342-5. PubMed ID: 17892128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface.
    Lécart S; Lecointe N; Subramaniam A; Alkan S; Ni D; Chen R; Boulay V; Pène J; Kuroiwa K; Tominaga S; Yssel H
    Eur J Immunol; 2002 Oct; 32(10):2979-87. PubMed ID: 12355452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-17 directly stimulates tumor infiltrating Tregs to prevent cancer development.
    Theune WC; Chen J; Theune EV; Ye X; Ménoret A; Vella AT; Wang K
    Front Immunol; 2024; 15():1408710. PubMed ID: 38947320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice.
    Molla Hassan AT; Hassan ZM; Moazzeni SM; Mostafaie A; Shahabi S; Ebtekar M; Hashemi SM
    Int Immunopharmacol; 2009 Nov; 9(12):1381-6. PubMed ID: 19706340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation.
    Ameri AH; Moradi Tuchayi S; Zaalberg A; Park JH; Ngo KH; Li T; Lopez E; Colonna M; Lee RT; Mino-Kenudson M; Demehri S
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2646-2651. PubMed ID: 30696763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells.
    Rizzo A; De Mare V; Rocchi C; Stolfi C; Colantoni A; Neurath MF; Macdonald TT; Pallone F; Monteleone G; Fantini MC
    Carcinogenesis; 2014 Jul; 35(7):1536-46. PubMed ID: 24480808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous IL-33 exerts CD8
    Xia Y; Ohno T; Nishii N; Bhingare A; Tachinami H; Kashima Y; Nagai S; Saito H; Nakae S; Azuma M
    Biochem Biophys Res Commun; 2019 Oct; 518(2):331-336. PubMed ID: 31421832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.
    Takenaga K; Akimoto M; Koshikawa N; Nagase H
    PLoS One; 2020; 15(4):e0232230. PubMed ID: 32340025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer.
    Lin YC; Mahalingam J; Chiang JM; Su PJ; Chu YY; Lai HY; Fang JH; Huang CT; Chiu CT; Lin CY
    Int J Cancer; 2013 Mar; 132(6):1341-50. PubMed ID: 22907255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated level of interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3.
    Ma Y; Chen L; Xie G; Zhou Y; Yue C; Yuan X; Zheng Y; Wang W; Deng L; Shen L
    Oncotarget; 2016 Nov; 7(45):73003-73015. PubMed ID: 27682874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity.
    Dupaul-Chicoine J; Arabzadeh A; Dagenais M; Douglas T; Champagne C; Morizot A; Rodrigue-Gervais IG; Breton V; Colpitts SL; Beauchemin N; Saleh M
    Immunity; 2015 Oct; 43(4):751-63. PubMed ID: 26384545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner.
    Eissmann MF; Dijkstra C; Wouters MA; Baloyan D; Mouradov D; Nguyen PM; Davalos-Salas M; Putoczki TL; Sieber OM; Mariadason JM; Ernst M; Masson F
    Cancer Immunol Res; 2018 Apr; 6(4):409-421. PubMed ID: 29463593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor.
    Yamaguchi T; Hirota K; Nagahama K; Ohkawa K; Takahashi T; Nomura T; Sakaguchi S
    Immunity; 2007 Jul; 27(1):145-59. PubMed ID: 17613255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells.
    Lee H; Lee H; Kwon Y; Lee JH; Kim J; Shin MK; Kim SH; Bae H
    J Immunol; 2010 Dec; 185(11):6698-705. PubMed ID: 21048105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
    Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
    Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ST2 as checkpoint target for colorectal cancer immunotherapy.
    Van der Jeught K; Sun Y; Fang Y; Zhou Z; Jiang H; Yu T; Yang J; Kamocka MM; So KM; Li Y; Eyvani H; Sandusky GE; Frieden M; Braun H; Beyaert R; He X; Zhang X; Zhang C; Paczesny S; Lu X
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer.
    Liu X; Zhu L; Lu X; Bian H; Wu X; Yang W; Qin Q
    Biochem Biophys Res Commun; 2014 Oct; 453(3):486-92. PubMed ID: 25280997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
    Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
    Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.